Semaglutide was the first GLP-1 medication widely adopted for medical weight loss. It works by mimicking the natural GLP-1 hormone, which helps control appetite, slow digestion, and improve insulin sensitivity. Patients using Semaglutide typically experience significant reductions in hunger and a gradual, steady decrease in body weight.
Clinical studies show an average of 15–17% total body weight loss when paired with lifestyle support. While it is highly effective, some patients may encounter plateaus or experience muscle loss alongside fat reduction.
Tirzepatide represents the next evolution in GLP-1 therapies. It acts on both GLP-1 and GIP receptors, providing dual benefits for weight management and metabolic health. GLP-1 reduces appetite and increases satiety, while GIP improves how the body processes and stores nutrients, creating a more efficient metabolism.
Clinical trials have demonstrated 20–22% total body weight loss, making Tirzepatide a stronger option than Semaglutide for many patients. With its enhanced fat-burning and nutrient-partitioning effects, Tirzepatide delivers faster results and improved energy balance.
Retatrutide (Next-GenerationRetatrutide is a breakthrough therapy that activates three receptors at once for unmatched results in weight management. By stimulating GLP-1, it powerfully reduces appetite and increases satiety. At the same time, it engages GIP to improve the way the body processes food and enhances insulin response. Finally, by activating the glucagon receptor, Retatrutide increases energy expenditure and accelerates fat burning.
Clinical research has shown up to 24% total body weight loss with Retatrutide — the highest of any GLP-1 medication to date. Unlike older therapies, it is particularly effective at targeting visceral fat (the dangerous belly fat around internal organs) while also helping to preserve lean muscle mass during weight loss. This means patients achieve not only greater fat reduction but also healthier, more sustainable results.
Most effective: Greater average weight loss vs. Semaglutide and Tirzepatide.
Targets belly fat more efficiently — up to 38% better visceral fat reduction.
Protects muscle & bone while promoting fat loss.
Cardiometabolic protection: lowers blood sugar, improves cholesterol, reduces cardiovascular risks more than comparators.
Next-generation therapy: combines three mechanisms for superior results and fewer weight-loss stalls.